Collectively, these pre-clinical and clinical results strongly support the development of therapeutic strategies targeting the IGF1/IGF1R axis to boost anti-cancer immunity and to potentially improve the efficacy of current immuno-oncotherapeutic approaches. This evidence concerns the gene IGF1 and cancer.